PUFAs may benefit MAFLD by improving obesity and insulin resistance, mainly by modulating gene expression of peroxisome proliferator-activated receptor alpha (PPARα), sterol regulatory element binding protein-1 (SREBP-1), and carbohydrate regulatory element binding protein (ChREBP) [64,65]. Here, SREBF1 is linked to obesity due to melanocortin 4 receptor deficiency.